

REMARKS

The Office Action dated March 3, 2006, has been carefully considered. The Applicants respectfully request reconsideration of the application in view of the foregoing amendments and the following remarks.

Claims 20 and 23-29 have been cancelled without prejudice. Claims 1-19, 21, 22, and 30-33 are pending following the above amendments. Claims 1-19 and 30-33 have been found to be allowable.

Election/Restrictions

Pursuant to a telephonic restriction under 35 U.S.C. 121 and 372, dated March 2, 2006, Applicants affirm the election with traverse of Group I, claims 1-19 and 30-33, drawn to compounds of formula I and their corresponding pharmaceutical compositions. The Examiner has indicated that a method of use claim that is of the same scope as the compound claim will be examined along with the compounds and pharmaceutical compositions because it would be considered to form a single inventive concept along with the compounds and pharmaceutical compositions of the same scope. For this purpose, the Applicants elect Group III, claims 21-22, drawn to a method of treating diabetes with a compound of Claim 1. Claims 20 and 23-29 are hereby withdrawn from further consideration as being drawn to non-elected subject matter.

Traverse of the restriction requirement is made on the grounds that the Examiner has not established an undue burden to examine in a single application the methods of Groups II, IV, V, VI, VII, and IX and the compositions of Group VIII. In the event that the restriction requirement is made final, Applicants elect Group I and III, as indicated above, holding the inventions defined by Groups II, IV, V, VI, VII, VIII, and IX in abeyance for further prosecution in a divisional application(s) at a later date.

Serial No.: 10/501,059
Case No.: 21247YP
Page No.: 19

The Applicants believe that all of the objections have been overcome by amendment, and they therefore earnestly solicit an early Notice of Allowance.

Respectfully submitted,

By 

Philippe L. Durette

Reg. No. 35,125

Attorney for Applicants

Merck & Co., Inc.

P.O. Box 2000

Rahway, NJ 07065-0907

(732) 594-4568

Date: March 14, 2006